Joo-Hang Kim

Joo-Hang Kim

UNVERIFIED PROFILE

Are you Joo-Hang Kim?   Register this Author

Register author
Joo-Hang Kim

Joo-Hang Kim

Publications by authors named "Joo-Hang Kim"

Are you Joo-Hang Kim?   Register this Author

100Publications

3554Reads

32Profile Views

Sonic Hedgehog Pathway as the Prognostic Marker in Patients with Extensive Stage Small Cell Lung Cancer.

Yonsei Med J 2019 Oct;60(10):898-904

Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3349/ymj.2019.60.10.898DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753348PMC
October 2019

Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.

Clin Cancer Res 2019 Mar 11;25(5):1612-1623. Epub 2018 Dec 11.

Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1932DOI Listing
March 2019

Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.

Lung Cancer 2018 09 27;123:14-21. Epub 2018 Apr 27.

Aix Marseille University, Jardin du Pharo, 58, bd Charles Livon, 13284 Marseille, France; Assistance Publique Hôpitaux de Marseille, 80, rue Brochier, 13005 Marseille, France; Centre d'Essais Précoces en Cancérologie de Marseille (CLIP(2)), Hôpital La Timone - Basement F, 1st Floor, 264, rue St Pierre, 13885 Marseille, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.04.022DOI Listing
September 2018

Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.

Lung Cancer 2018 08 24;122:234-242. Epub 2018 May 24.

Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.05.023DOI Listing
August 2018

Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea.

Lung Cancer 2018 05 6;119:36-41. Epub 2018 Mar 6.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.02.020DOI Listing
May 2018

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.

J Clin Oncol 2017 Aug 18;35(23):2613-2618. Epub 2017 May 18.

Sun Min Lim, Hye Ryun Kim, Hyo Sup Shim, Joo-Hang Kim, and Byoung Chul Cho, Yonsei University College of Medicine; Yun-Gyoo Lee, Yoon La Choi, and Myung-Ju Ahn, Sungkyunkwan University School of Medicine; Bong-Seog Kim, VHS Medical Center; Min Jeong Lee and Maria Kim, Yonsei University Health System, Seoul; Jong-Seok Lee and Jin-Haeng Chung, Seoul National University Bundang Hospital, Bundang; Ki Hyeong Lee, Chungbuk National University, Cheongju; Young Joo Min, University of Ulsan College of Medicine, Ulsan; Eun Kyung Cho, Gachon Medical School, Inchon; Sung Sook Lee, Inje University College of Medicine; Moon Young Choi, Inje University, Busan; Jin-Haeng Chung, Seoul National University College of Medicine, Seongnam, Republic of Korea; and Siraj M. Ali, Foundation Medicine, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.3701DOI Listing
August 2017

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

J Clin Oncol 2017 Apr 21;35(12):1288-1296. Epub 2017 Feb 21.

James Chih-Hsin Yang and Chia-Chi Lin, National Taiwan University Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan, Republic of China; Myung-Ju Ahn, Sungkyunkwan University; Dong-Wan Kim, Seoul National University Hospital; Sang-We Kim, Asan Medical Center, Seoul; Joo-Hang Kim, CHA University, Gyeonggi-do, Republic of Korea; Suresh S. Ramalingam, Emory University School of Medicine, Atlanta, GA; Lecia V. Sequist, Massachusetts General Hospital; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; David Planchard, Institut Gustave Roussy, Villejuif, France; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Fiona Blackhall, The Christie Hospital; University of Manchester, Manchester; Helen Mann and Serban Ghiorghiu, AstraZeneca, Cambridge; Mireille Cantarini, AstraZeneca, Macclesfield, United Kingdom; Daniel Haggstrom, Carolinas Healthcare System, Charlotte, NC; Kiyotaka Yoh, National Cancer Center Hospital East, Kashiwa, Chiba; Tomonori Hirashima, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan; Silvia Novello, University of Turin, Turin, Italy; and Kathryn Gold, University of California San Diego Moores Cancer Center, San Diego, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.70.3223
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.70.3223DOI Listing
April 2017

Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.

Cancer 2016 Oct 17;122(19):3024-31. Epub 2016 Jun 17.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30135DOI Listing
October 2016

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.

J Clin Oncol 2016 09 9;34(27):3258-66. Epub 2016 Aug 9.

Ying Cheng, Jilin Provincial Cancer Hospital, Changchun; Jianxing He, The First Affiliated Hospital of Guangzhou Medical University, Guangdong; Xin Wang, Eli Lilly, Shanghai, China; Haruyasu Murakami, Shizuoka Cancer Center, Shizuoka; Kazuhiko Nakagawa, Kinki University School of Medicine, Osaka; Sotaro Enatsu, Eli Lilly Japan, Kobe, Japan; Pan-Chyr Yang and James Chih-Hsin Yang, National Taiwan University Hospital; James Chih-Hsin Yang, National Taiwan University Cancer Center, Taipei, Taiwan; Jin Hyoung Kang, The Catholic University of Korea, Seoul; Joo-Hang Kim, CHA Bundang Medical Center, CHA University, Gyeonggi-do, Korea; Tarun Puri, Eli Lilly, Gurgaon, Haryana, India; and Mauro Orlando, Eli Lilly Interamérica, Buenos Aires, Argentina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.9218DOI Listing
September 2016

EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.

Mol Cancer Ther 2016 07 11;15(7):1627-36. Epub 2016 May 11.

Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0375DOI Listing
July 2016

Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma.

Head Neck 2016 04 18;38 Suppl 1:E1653-9. Epub 2016 Feb 18.

Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.24294DOI Listing
April 2016

Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy.

Pharmacogenet Genomics 2016 Mar;26(3):116-25

aDepartment of Pharmacology and Brain Korea 21 Plus Project for Medical Sciences bDepartment of Internal Medicine, Division of Medical Oncology cDepartment of Nuclear Medicine, College of Medicine, Yonsei University, Seoul dDepartment of Internal Medicine, Division of Medical Oncology, CHA University Bundang Medical Center, Seongnam eDepartment of Pharmacology and PharmacoGenomics Research Center, College of Medicine, Inje University, Busan, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000196DOI Listing
March 2016

Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells.

Apoptosis 2016 Mar;21(3):351-64

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10495-015-1208-zDOI Listing
March 2016

A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.

Cancer Chemother Pharmacol 2016 Mar 25;77(3):539-48. Epub 2016 Jan 25.

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-Gu, Seoul, 120-752, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-2968-zDOI Listing
March 2016

A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).

Lung Cancer 2016 Mar 29;93:1-8. Epub 2015 Dec 29.

Division of Medical Oncology, Department of Internal Medicine, CHA University Bundang Medical Center, Seongnam, South Korea; Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.12.005DOI Listing
March 2016

Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.

BMC Cancer 2016 Mar 16;16:224. Epub 2016 Mar 16.

Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-016-2251-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793740PMC
March 2016

Definitive Chemoradiotherapy Versus Surgery Followed by Adjuvant Radiotherapy in Resectable Stage III/IV Hypopharyngeal Cancer.

Cancer Res Treat 2016 Jan 13;48(1):45-53. Epub 2015 Mar 13.

Department of Radiation Oncology, Yonsei Cancer Hospital, Yonsei University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2014.340DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720057PMC
January 2016

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

J Clin Oncol 2015 Dec 31;33(34):4007-14. Epub 2015 Aug 31.

Karen Kelly, University of California, Davis, Comprehensive Cancer Center, Sacramento, CA; Nasser K. Altorki, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY; Wilfried E.E. Eberhardt, University Hospital Essen, Essen, Germany; Mary E.R. O'Brien, Royal Marsden Hospital, London, United Kingdom; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Lucio Crinò, Ospedale S. Maria della Misericordia, Perugia, Italy; Chun-Ming Tsai, Taipei General Hospital and National Yang-Ming University, Taipei, Taiwan; Joo-Hang Kim, Yonsei University Health System, Seoul; Eun Kyung Cho, Gachon University, Incheon, Korea; Philip C. Hoffman, The University of Chicago Medical Center, Chicago; Jiuzhou Wang and Margaret A. Foley, Astellas Pharma, Northbrook, IL; Sergey V. Orlov, I.P. Pavlov Medical University, St Petersburg, Russia; Piotr Serwatowski, Specjalistyczny Szpital, Sokolowskiego, Szczecin, Poland; Julie D. Horan, Novella Clinical, Boulder, CO; and Frances A. Shepherd, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/08/31/JCO.2015.61
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.61.8918
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.61.8918DOI Listing
December 2015

Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma.

Mol Cancer Ther 2015 Oct 24;14(10):2238-48. Epub 2015 Jul 24.

Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. Institute for Cancer Research, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0350DOI Listing
October 2015

An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer.

Eur J Cancer 2015 Aug 9;51(12):1588-95. Epub 2015 Jun 9.

Department of Internal Medicine, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.05.020DOI Listing
August 2015

Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.

J Clin Oncol 2015 Aug 6;33(24):2660-6. Epub 2015 Jul 6.

Jin Seok Ahn, Yong Chan Ahn, Yoon-La Choi, Jong-Mu Sun, Myung-Ju Ahn, and Keunchil Park, Samsung Medical Center, Sungkyunkwan University School of Medicine; Joo-Hang Kim and Chang Geol Lee, Yonsei Cancer Center, Yonsei University Health System; Dong-Wan Kim, Seoul National University Hospital; Jin-Hyoung Kang, Catholic University Seoul St Mary's Hospital; Sung Rok Kim, Inje University Sanggye Paik Hospital; Sang-We Kim, Asan Medical Center, University of Ulsan College of Medicine; Sin-Ho Jung, Samsung Medical Center, Office of Biomedical Science, Seoul; Eun Kyung Cho and Kyu Chan Lee, Gachon University Gil Medical Center, Incheon; Hoon-Kyo Kim, Catholic University St Vincent's Hospital; Jin-Hyuck Choi, Ajou University Hospital, Suwon; Young Joo Min, Ulsan University Hospital, Ulsan; Kyung Hee Lee, Yeungnam University Medical Center; Hong Suk Song, Keimyung University Dongsan Medical Center, Daegu, Korea; Ming Chen, Sun Yat-Sen University Cancer Center, Guangzhou; Guangying Zhu, Beijing Cancer Hospital, Beijing; Yi-Long Wu, Guandong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangdong, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.0130DOI Listing
August 2015

Silencing Daxx increases the anti-tumor activity of a TRAIL/shRNA Bcl-xL-expressing oncolytic adenovirus through enhanced viral replication and cellular arrest.

Cell Signal 2015 Jun 5;27(6):1214-24. Epub 2015 Mar 5.

Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08986568150007
Publisher Site
http://dx.doi.org/10.1016/j.cellsig.2015.02.028DOI Listing
June 2015

Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells.

Cell Signal 2015 Apr 20;27(4):807-17. Epub 2015 Jan 20.

Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellsig.2015.01.007DOI Listing
April 2015

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

N Engl J Med 2015 Apr;372(18):1689-99

From the Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston (P.A.J.); National Taiwan University and National Taiwan University Hospital (J.C.-H.Y.) and Cheng Kung University Hospital (W.-C.S.) - both in Taipei, Taiwan; Seoul National University Hospital (D.-W.K.), Samsung Medical Center (M.-J.A.), Asan Medical Center (S.-W.K.), and Yonsei Cancer Center, Yonsei University Health System (J.-H.K.) - all in Seoul, South Korea; Institut Gustave Roussy, Villejuif, France (D.P.); National Cancer Center Hospital, Tokyo (Y.O.); Winship Cancer Institute of Emory University, Atlanta (S.S.R.); Vanderbilt Ingram Cancer Center, Nashville (L.H.); Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC (D.H.); Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona (E.F.); and AstraZeneca, Macclesfield (P.F., M.C., K.H.B., P.A.D., S.G.), and University of Manchester, Christie Hospital, Manchester (M.R.) - both in the United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1411817DOI Listing
April 2015

Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.

Lung Cancer 2015 Feb 29;87(2):148-54. Epub 2014 Nov 29.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.11.013DOI Listing
February 2015

Identification and clinical implications of circulating microRNAs for estrogen receptor-positive breast cancer.

Tumour Biol 2014 Dec 3;35(12):12173-80. Epub 2014 Sep 3.

Center for Breast Cancer, National Cancer Center, Madu-dong, Ilsandong-gu, Goyangsi, South Korea,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13277-014-2525-5DOI Listing
December 2014

Establishment of a mouse melanoma model system for the efficient infection and replication of human adenovirus type 5-based oncolytic virus.

Biochem Biophys Res Commun 2014 Oct 1;453(3):480-5. Epub 2014 Oct 1.

Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2014.09.107DOI Listing
October 2014

Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations.

Cancer 2014 Jul 15;120(14):2090-8. Epub 2014 Apr 15.

Lung Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea; Department of Medicine, Graduate School, Yonsei University, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28711DOI Listing
July 2014

Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.

Lung Cancer 2014 May 3;84(2):196-202. Epub 2014 Feb 3.

Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.01.022DOI Listing
May 2014

A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer.

Cancer Chemother Pharmacol 2014 Apr 22;73(4):665-71. Epub 2014 Feb 22.

Yonsei Cancer Center, Yonsei University Health System, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2371-yDOI Listing
April 2014

Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.

Lung Cancer 2014 Mar 14;83(3):389-95. Epub 2014 Jan 14.

Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.01.003DOI Listing
March 2014

Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma.

Lung Cancer 2014 Mar 3;83(3):374-82. Epub 2014 Jan 3.

Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.12.011DOI Listing
March 2014

Reply to B.M. Strebel.

J Clin Oncol 2014 Feb 30;32(5):479-80. Epub 2013 Dec 30.

Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille; Centre Investigation Clinique, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.7175DOI Listing
February 2014

Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer.

Breast 2013 Dec 14;22(6):1205-9. Epub 2013 Oct 14.

Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.08.013DOI Listing
December 2013

S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.

BMC Cancer 2013 Dec 6;13:583. Epub 2013 Dec 6.

Yonsei Cancer Center, Divison of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-13-583DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029391PMC
December 2013

Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089).

J Thorac Oncol 2013 Nov;8(11):1409-16

*Department of Thoracic Oncology, Lungenfachklinik Immenhausen, Immenhausen, Germany; †N.N. Blokhin Cancer Research Center of Russia, Moscow, Russia; ‡Department of Pulmonary Medicine, Lungkliniken, Linköping, Sweden; §Pulmonary and Thoracic Oncology Department, Hôpital Albert Calmette, CHRU de Lille, Lille, France; ‖Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea; ¶Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; #Department of Cardio-Thoracic Medicine, University of Pisa, Pisa, Italy; **Service de Pneumologie, Assistance Publique - Hopitaux de Paris, Hôpital Saint-Antoine, Paris, France; ††Global Medical Affairs, Genentech, Inc., South San Francisco, California; and ‡‡Service d' Oncologie Multidisciplinaire & Innovations Thérapeutiques, Aix Marseille University, Assistance Publique Hopitaux de Marseille, INSERM CIC, Multidisciplinary Oncology and Therapeutic Innovations, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182a46bcfDOI Listing
November 2013

Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation.

Mol Cancer Ther 2013 Oct 24;12(10):2145-56. Epub 2013 Jul 24.

Corresponding Authors: Byoung Chul Cho, Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-1188DOI Listing
October 2013

Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater.

Tohoku J Exp Med 2013 09;231(1):21-8

Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1620/tjem.231.21DOI Listing
September 2013

Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung.

Yonsei Med J 2013 Jul;54(4):854-64

Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3349/ymj.2013.54.4.854DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663241PMC
July 2013

Crosstalk from survival to necrotic death coexists in DU-145 cells by curcumin treatment.

Cell Signal 2013 May 24;25(5):1288-300. Epub 2013 Jan 24.

Institute for Cancer Research, College of Medicine, Yonsei University, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellsig.2013.01.014DOI Listing
May 2013

The effectiveness of the oncolytic activity induced by Ad5/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagy.

Int J Oncol 2013 Apr 7;42(4):1337-48. Epub 2013 Feb 7.

Institute for Cancer Research, College of Medicine, Yonsei University, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2013.1812DOI Listing
April 2013

Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.

Eur J Cancer 2013 Apr 7;49(6):1205-15. Epub 2013 Mar 7.

Korányi National Institute for TB and Pulmonology, Budapest, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2012.11.006DOI Listing
April 2013

A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).

Lung Cancer 2013 Mar 20;79(3):270-5. Epub 2012 Dec 20.

Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2012.11.017DOI Listing
March 2013

TRAIL/MEKK4/p38/HSP27/Akt survival network is biphasically modulated by the Src/CIN85/c-Cbl complex.

Cell Signal 2013 Jan 23;25(1):372-9. Epub 2012 Oct 23.

Institute for Cancer Research, College of Medicine, Yonsei University, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08986568120029
Publisher Site
http://dx.doi.org/10.1016/j.cellsig.2012.10.010DOI Listing
January 2013

EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI.

Yonsei Med J 2012 Nov;53(6):1128-35

Department of Pharmacology, Pharmacogenomic Research Center for Membrane Transporters and Research Center for Human Natural Defense System, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3349/ymj.2012.53.6.1128DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481391PMC
November 2012

The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.

Cancer Chemother Pharmacol 2012 Oct 7;70(4):539-46. Epub 2012 Aug 7.

Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seodaemun-gu, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-012-1933-8DOI Listing
October 2012

Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.

Mol Cancer Ther 2012 Oct 13;11(10):2254-64. Epub 2012 Aug 13.

Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-0311DOI Listing
October 2012

Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer.

BMC Cancer 2012 Sep 7;12:392. Epub 2012 Sep 7.

Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://bmccancer.biomedcentral.com/articles/10.1186/1471-240
Publisher Site
http://dx.doi.org/10.1186/1471-2407-12-392DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475052PMC
September 2012

Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.

Lung Cancer 2012 Aug 10;77(2):339-45. Epub 2012 Apr 10.

Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou 510080, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2012.03.012DOI Listing
August 2012

Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer.

Anticancer Res 2012 Aug;32(8):3515-21

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University, 50 Yonseiro, Seodaemoon-gu, Seoul 120-752, Korea.

View Article

Download full-text PDF

Source
August 2012

HSP27 modulates survival signaling networks in cells treated with curcumin and TRAIL.

Cell Signal 2012 Jul 15;24(7):1444-52. Epub 2012 Mar 15.

Institute for Cancer Research, College of Medicine, Yonsei University, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08986568120008
Publisher Site
http://dx.doi.org/10.1016/j.cellsig.2012.03.009DOI Listing
July 2012